Tessa Therapeutics Pte Ltd

The pace of cancer partnering between the biopharma industry and academic and institutional research entities during the final months of 2022 remained typically brisk, and two US institutions – The U

The number of biopharmaceutical companies raising venture capital this year has far outpaced the number raising money in public offerings, with 126 venture rounds during the first quarter versus just

Gene therapies that bluebird bio and CRISPR Therapeutics / Vertex Pharmaceuticals are developing respectively for sickle cell disease have made it onto the European Medicines Agency’s priority med

Having successfully navigated a two-day, virtual advisory committee review of cancer drug pediatric development plans, the US Food and Drug Administration is ready to embark on its first application-s